Early patient successes and limits

Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle.

• SOURCES:
  • Chris Snyder, professor of economics at Dartmouth College.
  • David Fajgenbaum, co-founder and president of Every Cure, physician-scientist at the University of Pennsylvania.
  • Heather Stone, health science policy analyst at the Food & Drug Administration.
  • Sarrin Chethik, senior policy analyst at the Market Shaping Accelerator.

• RESOURCES:
  • Chasing My Cure: A Doctor's Race to Turn Hope into Action; A Memoir, by David Fajgenbaum (2019).
  • Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases, by Michael Kremer and Rachel Glennerster (2016).
  • Market Shaping Accelerator.
  • CURE ID Registry.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.